Skip to content
Advertisement

FILE - In this March 16, 2020 file photo, a pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. Tens of thousands of Americans have volunteered to test COVID-19 vaccines, but only about half of them got the real thing. Now, with the first vaccine rollouts and a surge in coronavirus infections, experts are debating what to do about the half that got a dummy shot. (AP Photo/Ted S. Warren, File)

FILE - In this March 16, 2020 file photo, a pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. Tens of thousands of Americans have volunteered to test COVID-19 vaccines, but only about half of them got the real thing. Now, with the first vaccine rollouts and a surge in coronavirus infections, experts are debating what to do about the half that got a dummy shot. (AP Photo/Ted S. Warren, File)

Featured Photo Galleries